Cardiovascular Risk Estimation and Eligibility for Statins in Primary Prevention Comparing Different Strategies

被引:12
|
作者
Nanchen, David [1 ,2 ]
Chiolero, Arnaud [2 ]
Cornuz, Jacques [1 ]
Marques-Vidal, Pedro-Manuel [2 ]
Firmann, Mathieu [3 ]
Mooser, Vincent [4 ]
Paccaud, Fred [2 ]
Waeber, Gerard [3 ]
Vollenweider, Peter [3 ]
Rodondi, Nicolas [1 ]
机构
[1] Univ Lausanne, Univ Hosp Ctr, Dept Ambulatory Care & Community Med, Lausanne, Switzerland
[2] Univ Lausanne, Univ Hosp Ctr, Inst Social & Prevent Med, Lausanne, Switzerland
[3] Univ Lausanne, Univ Hosp Ctr, Dept Med, Lausanne, Switzerland
[4] GlaxoSmithKline, Div Genet, King Of Prussia, PA USA
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2009年 / 103卷 / 08期
关键词
CORONARY-HEART-DISEASE; EUROPEAN GUIDELINES; FRAMINGHAM; POPULATION; THERAPY; SCORE; EPIDEMIOLOGY; PARTICIPANTS; METAANALYSIS; MORTALITY;
D O I
10.1016/j.amjcard.2008.12.042
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recommendations for statin use for primary prevention of coronary heart disease (CHID) are based on estimation of the 10-year CHD risk. It is unclear which risk algorithm and guidelines should be used in European populations. Using data from a population-based study in Switzerland, we first assessed 10-year CHD risk and eligibility for statins in 5,683 women and men 35 to 75 years of age without cardiovascular disease by comparing recommendations by the European Society of Cardiology without and with extrapolation of risk to age 60 years, the International Atherosclerosis Society, and the US Adult Treatment Panel III. The proportions of participants classified as high-risk for CHD were 12.5% (15.4% with extrapolation), 3.0%, and 5.8%, respectively. Proportions of participants eligible for statins were 9.2% (11.6% with extrapolation), 13.7%, and 16.7%, respectively. Assuming full compliance to each guideline, expected relative decreases in CHD deaths in Switzerland over a 10-year period would be 16.4% (17.5% with extrapolation), 18.7%, and 19.3%, respectively; the corresponding numbers needed to treat to prevent 1 CHD death would be 285 (340 with extrapolation), 380, and 440, respectively. In conclusion, the proportion of subjects classified as high risk for CHD varied over a fivefold range across recommendations. Following the International Atherosclerosis Society and the Adult Treatment Panel III recommendations might prevent more CHD deaths at the cost of higher numbers needed to treat compared with European Society of Cardiology guidelines. (C) 2009 Elsevier Inc. All rights reserved. (Am J Cardiol 2009;103:1089-1095)
引用
收藏
页码:1089 / 1095
页数:7
相关论文
共 50 条
  • [21] Statins for the primary prevention of cardiovascular disease
    Taylor, Fiona
    Huffman, Mark D.
    Macedo, Ana Filipa
    Moore, Theresa H. M.
    Burke, Margaret
    Smith, George Davey
    Ward, Kirsten
    Ebrahim, Shah
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (01):
  • [22] Primary prevention of cardiovascular disease with statins: cautionary notes
    Goldstein, M. R.
    Mascitelli, L.
    Pezzetta, F.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2009, 102 (11) : 817 - 820
  • [23] Statins and ASS for primary prevention of cardiovascular and cerebrovascular disease
    Goltz, L.
    Bodechtel, U.
    Siepmann, T.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2014, 139 (06) : 283 - 286
  • [24] Cardiovascular Risk and Statin Eligibility in Primary Prevention: A Comparison between the Brazilian and the AHA/ACC Guidelines
    Cesena, Fernando H. Y.
    Valente, Viviane A.
    Santos, Raul D.
    Bittencourt, Marcio S.
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2020, 115 (03) : 440 - 448
  • [25] Statins for primary prevention of cardiovascular disease and the risk of acute kidney injury
    Coste, Joel
    Karras, Alexandre
    Rudnichi, Annie
    Dray-Spira, Rosemary
    Pouchot, Jacques
    Giral, Philippe
    Zureik, Mahmoud
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 (12) : 1583 - 1590
  • [26] Beyond 10-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease
    Kohli-Lynch, Ciaran N.
    Lewsey, James
    Boyd, Kathleen A.
    French, Dustin D.
    Jordan, Neil
    Moran, Andrew E.
    Sattar, Naveed
    Preiss, David
    Briggs, Andrew H.
    CIRCULATION, 2022, 145 (17) : 1312 - 1323
  • [27] Compliance in Primary Prevention With Statins and Associations With Cardiovascular Risk and Death in a Low-Risk Population With Type 2 Diabetes Mellitus
    Malmborg, Morten
    Schmiegelow, Michelle D. S.
    Gerds, Thomas
    Schou, Morten
    Kistorp, Caroline
    Torp-Pedersen, Christian
    Gislason, Gunnar
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (13):
  • [28] Accuracy of cardiovascular risk estimation for primary prevention in patients without diabetes
    Reynolds, TM
    Twomey, P
    Wierzbicki, AS
    JOURNAL OF CARDIOVASCULAR RISK, 2002, 9 (04): : 183 - 190
  • [29] Primary Prevention of Cardiovascular Disease with Statins in the Elderly
    Reiner, Zeljko
    CURRENT ATHEROSCLEROSIS REPORTS, 2014, 16 (07)
  • [30] Statins for the primary prevention of cardiovascular disease in women?
    Birge, Stanley J.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2012, 19 (12): : 1287 - 1288